To the Editor.
—Flurbiprofen sodium (0.03%) (Ocufen) is a recently approved nonsteroidal anti-inflammatory drug for the maintenance of intraoperative pupillary dilation during cataract surgery. Initial reports of its efficacy have been favorable.1,2 There have been few reports of side effects. The package insert states that the most frequent reactions are transient burning and stinging on instillation. The insert also states that there is a hypothetical possibility of intraoperative hemorrhage via interference with thrombocyte aggregation. I recently encountered a perioperative complication that may be attributed to interference with the clotting mechanism.
Report of a Case.
—An 84-year-old man was scheduled to undergo extracapsular cataract extraction in the left eye with posterior chamber lens implantation. Before surgery, the patient was taking chlorpropamide and dipyridamole. One hour and 30 minutes before surgery, one drop of 0.03% flurbiprofen sodium was instilled into the left eye. In addition, 1% tropicamide and 2.25% phenylephrine
Feinstein NC, Rubin B. Toxicity of Flurbiprofen Sodium. Arch Ophthalmol. 1988;106(3):311. doi:10.1001/archopht.1988.01060130337009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: